Piramal enterprises share price

Sector Finance Compare with Sector peers Industry Finance - NBFC Compare with Industry peers Website http://www.piramal.com Market Cap 19,113.38 Cr. Enterprise Value(EV) Cr. - Financial Indicators • Consolidated • Standalone Earnings per share (EPS) 417.68 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) 1.92 Trailing Twelve Months Ending 2023-03 Industry PE 22.12 Trailing Twelve Months Ending 2023-03 Book Value / Share 1,301.37 Trailing Twelve Months Ending 2023-03 Price to Book Value 0.62 Calculated using Price: 800.85 Dividend Yield 3.87 Period Ending 2023-03 No. of Shares Subscribed 23.87 Cr. 238,663,700 Shares FaceValue 2 About Piramal Enterprises Ltd. Piramal Enterprises Limited (PEL) is one of India's leading diversified companies, with a presence in Financial Services and Pharmaceuticals. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence. Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. Shh. Funds 9,321 11,736 12,948 14,883 26,562 27,224 30,572 34,018 35,489 31,059 NonCurr.Liab. 6,710 7,817 11,760 18,776 25,355 29,033 24,454 34,163 58,713 50,049 Curr. Liab. 9,490 5,694 10,542 18,962 22,479 31,213 23,673 13,873 11,249 8,428 Minority Int. 29 0 13 12 9 1,121 1,348 Equity & Liab. 25,521 25,276 35,250 52,634 74,409 87,480 78,699 83,175 106,799 ...

Period Mar 2023 Mar 2022 Mar 2021 Mar 2020 Total Revenue 9061.77 7811.30 12809.35 13068.29 Selling/ General/ Admin Expenses Total 1904.92 985.69 2810.71 2733.76 Depreciation/ Amortization 117.32 74.28 560.88 520.30 Other Operating Expenses Total 60.33 39.23 73.71 109.69 Total Operating Expense -5024.20 2274.96 5940.83 7320.92 Operating Income 14085.97 5536.34 6868.52 5747.37 Net Income Before Taxes 5990.53 2068.43 3455.77 1407.12 Net Income 9968.58 1923.11 1332.34 24.03 Diluted Normalized EPS 193.75 94.03 56.26 31.64 • Name • Latest Price • Change • % Change • 52W High • 52W Low • Mkt. Cap • • 376.6 • 3.85 • 1.03 • 443.5 • 291.75 • 20728.06 • • 1191.05 • -26.35 • -2.16 • 1291.55 • 834.1 • 18926.55 • • 800.85 • 0.35 • 0.04 • 1141.75 • 630.2 • 19113.38 • • 497 • 1.2 • 0.24 • 538.4 • 305.3 • 18907.39 • • 591 • -13.35 • -2.21 • 687.25 • 448.2 • 17219.74 Meeting Date Purpose 05-May-23 Audited Results & Final Dividend 08-Feb-23 Quarterly Results 09-Nov-22 Quarterly Results 29-Jul-22 Quarterly Results 14-Jul-22 To consider raising of funds 26-May-22 Audited Results & Final Dividend 10-Feb-22 Quarterly Results 11-Nov-21 Quarterly Results 06-Aug-21 Quarterly Results 13-May-21 Audited Results & Final Dividend ABOUT Piramal Enterprises • Industry Consumer Financial Services • ISIN INE140A01024 • BSE Code 500302 • NSE Code PEL Piramal Enterprises Limited (PEL) is an India-based company that is engaged in diversified business, such as financial services and pharmaceuticals. PEL’s finan...

Piramal Enterprises is looking at sustained growth and profitability with the last few years spent in making balance sheets and businesses more resilient to tide over unforeseen uncertainties, according to Chairman Ajay G Piramal. In his address to shareholders in Annual Report for 2022-23, the business leader said the efforts over the last years have shown positive results with the group ending the last fiscal with a net profit of Rs 9,969 crore and total assets of Rs 83,386 crore. ''We are now focused on sustained growth and profitability and to achieve our balance between three pillars - Growth, Risk and Profitability,'' Piramal stated. Focused business entities ensure not only focus in terms of business strategies but also help strengthen and ensure efficient use of our capital and human resources, he added. ''We are certain that the consequent long-term value creation for all stakeholders will be achieved by strategically selecting our specialised bets in retail and wholesale backed by cutting-edge technology, assiduous risk management and exceptional leadership,'' Piramal said. He noted that creating two separate pure-play entities in the financial services and pharmaceuticals has resulted in a stronger governance architecture, with dedicated Board and management teams for the two businesses. ''The demerger allows us to ensure optimal capital structures for each business and will facilitate the businesses to grow independently, by pursuing both organic and inorganic ...

• Company has maintained a good ROA of 13.2291722445164% in last 3 years. • Company has a healthy Return on Equity (ROE) track record of 21.0426543441968%. • TThe company has been maintaining a healthy ROCE of 19.0055383488204% since last 3 years. • The company is trading at 0.672872646502269 times the book value • Operating Income has grown well for the company over past 3 years: 3 years CAGR 33.4625347158109%. • The company has delivered substantial profit growth of 0% over past 3 years. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Operating Revenue 804.25 513.27 455.04 3763.21 180.53 Other Income 30.27 42.77 20.82 10.7 8.52 Interest Expended 258.4 155.72 150.32 164.54 166.78 Operating Expenses 302.51 362.35 970.97 650.29 30.62 Total Provisions 0 0 452.3 0 0 Depreciation 6.24 5.6 6.88 8.47 2.13 Profit Before Tax 267.37 32.37 -1104.61 2950.61 -10.48 Tax 23.37 4.29 -149.5 58.41 46.4 Net Profit 261.32 28.08 -50.51 2892.2 -56.88 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Operating Income 3670.85 2012.89 1824.7 2718.54 4785.22 Other Income 471.64 741.95 286.03 129.91 161.56 Interest 1497.27 1710.06 1068.77 1243.37 711.77 Operating Expenses 2087 403.42 702.95 340.75 254.75 Total Provisions 67.87 365.72 149.87 76.89 1581.58 Exceptional Items -1287.96 0 -258.34 -10.2 11912.22 Profit Before Tax -797.61 275.64 -69.2 1177.24 14310.9 Tax 70.4 390.4 51.02 213.04 -22....

Piramal Enterprises share price trades ex-demerger ahead of record date, what should investors know The company’s board earlier in October 2021 had approved the demerger of Piramal Ent and Piramal Pharma as two separated entities. The former to handle financial services business and the latter to have a pharmaceutical business. • • • • • At the market close, shares of PEL jumped over 1 per cent higher to Rs 1,062.75 per share on the BSE. The counter opened at the ex-demerger price of Rs 1,050 apiece on the BSE. Piramal Enterprises' demerger record date is September 1, 2022 and the company will issue 4 equity shares of Rs 10 each of Piramal Pharma for every 1 equity share of Rs 2 each to shareholders of Piramal Enterprises Limited. Piramal Enterprises will have a financial services business, including retail and wholesale lending, while Piramal Pharma, which will be relisted on exchanges after the demerger, would have a pharma, and CDMO business, according to Zee Business research analyst Nupur Jainkunia. The pharma entity will be listed in the next 3-4 quarters of the ongoing fiscal year, the analyst said. On the book value of 1.3/1.4 times, Piramal Enterprises' share price comes to Rs 1415 per share with respect to FY24e and Piramal Pharma's share price comes to Rs 915 per share on 17 times EV/EBITDA on an average after factoring 20 per cent holding discount, Zee Business analyst The total share price value comes to Rs 2330 per share, which shows around an 18-20 per cent ...

Description • Piramal Enterprises Ltd is within the Pharmaceuticals sector with a Market Capitalization worth Rs. 62,921.38 crores, it is incorporated in the year 1984. It has reported consolidated sales of Rs. 2908.68 crores in June’2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500302, and also listed on the National Stock Exchange (NSE) with the code PEL. Piramal Enterprises Ltd, earlier referred as Piramal Healthcare Ltd is that the largest company under the management of the Piramal Group led by Ajay Piramal. It mainly operates in three different type of divisions, i.e., Financial Services, Pharmaceuticals, and Healthcare Insights & Analytics. In the pharmaceuticals division, Piramal Enterprises Ltd has set up a global production chain with manufacturing facilities installed in 13 countries in the world. Piramal Enterprises Ltd has also set up a global distribution network in over a hundred nations. In financial services, PEL provides wholesale lending for housing finance & PEL has also ventured into Alternate Capital Management. The promoters of the company own 43.52% of the stake in the company, Foreign Institutional Investors (FII) own 33.27%, Domestic Institutional Investors (DII) own 9.81% stake in the company, and others (such as public & retail investors) hold the balance of 13.40%. As of 30th June 2021, quarterly net revenue was Rs. 512.78 crores, which has increased by approximately 44.64% from Rs. 354.51 crores for the April-Jun...

Analysts maintained their positive view of Piramal Enterprises citing a positive risk-to-reward ratio after the company demerged its pharmaceutical business. The company had fixed September 1, 2022 as the demerger of Piramal Pharma record date. While retaining its bullish view on Piramal Enterprises post demerger, ICICI Securities said that lending business with FY22 allocated net worth of Rs 17,000 crore will generate RoE of 8-9 per cent over FY23-24E and can command multiple of 1.15 times book. It also added that investments in Shriram Group have been valued at Rs 5,500 crore or Rs 230 per share. “We value Piramal Enterprises financial services business (factoring demerger of pharma business) at Rs 33,200 crore or Rs 1,391 per share,” ICICI Securities said adding it assigned Rs 3,800 crore, or Rs 161 per share, for unallocated equity, alternatives and life insurance. Adjusted share price Piramal Enterprises traded 1.41 per cent higher at Rs 1,042.55 in the morning trade on September 2. On the other hand, the benchmark BSE Sensex was down nearly 33 points, or 0.06 per cent, at 58,733. Market watchers believe that equity shares, proposed to be allotted by PPL (Piramal Pharma Limited), are expected to be listed on stock exchanges over the next 2-3 months, subject to necessary regulatory approvals. Each Piramal Enterprises shareholder will get 4 shares of Piramal Pharma. On the other hand, global brokerage firm Jefferies is also positive on Piramal Enterprises with a tar...

Als u op ' Alles accepteren' klikt, gebruiken wij en • gepersonaliseerde advertenties en content weergeven op basis van interesseprofielen • de effectiviteit meten van gepersonaliseerde advertenties en content, en • onze producten en services ontwikkelen en verbeteren Als u niet wilt dat wij en onze partners cookies en persoonsgegevens voor deze aanvullende doeleinden gebruiken, klik dan op ' Alles weigeren'. Als u uw keuzes wilt aanpassen, klik dan op ' Privacyinstellingen beheren'. Je kunt je keuzes te allen tijde wijzigen door te klikken op de links 'Privacy- en cookie-instellingen' of 'Privacydashboard' op onze sites en in onze apps. Lees ons

Piramal Enterprises Limited (PEL) is an India-based company that is engaged in diversified business, such as financial services and pharmaceuticals. PEL’s financial services offer a range of financial products and solutions, with wholesale and retail financing. The wholesale lending business provides financing to real estate developers, as well as corporate. Within retail lending, PEL is engaged in building a multi-product platform and offers home loans, loans for small businesses and loans for working capital to its customers. The Company offers India Resurgence Fund (IndiaRF), the distressed asset investing platform, which invests in equity and/or debt across non-real estate sectors. Its financial services also include alternative assets and investments in Shriram Group. PEL has a differentiated business model that is diversified across three segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare.;